Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...
Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback